Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks
05:34am, Tuesday, 24'th Dec 2024
Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses.
Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note
06:51pm, Monday, 23'rd Dec 2024
In the most recent trading session, Johnson & Johnson (JNJ) closed at $145.27, indicating a +0.55% shift from the previous trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Monday, 23'rd Dec 2024
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
RxSight downgraded to Hold from Buy at Stifel
07:55pm, Thursday, 19'th Dec 2024
Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL - intra
Johnson & Johnson: Dividend Legend At A Discount
11:00am, Thursday, 19'th Dec 2024
Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage, ampl
Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now
08:46am, Thursday, 19'th Dec 2024
The Dow Jones industrial average is a price-weighted index of 30 blue-chip U.S.
Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy
02:15pm, Wednesday, 18'th Dec 2024
The June/July, 2024 Fortune Magazine revealed 500 biggest U.S. companies by-revenue and profits. Arnold-research focused on 66 December industry-leaders using YCharts 12/13/24 data for Profits from 63
Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients
01:06pm, Wednesday, 18'th Dec 2024
The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a tr
The Smartest Dividend Stocks to Buy With $500 Right Now
05:15am, Wednesday, 18'th Dec 2024
As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend s
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months f
Barclays fact-checked Trump comments on pharmacy benefit managers
01:40pm, Tuesday, 17'th Dec 2024
Barclays analyst Andrew Mok said that while the existential risk to pharmacy benefit managers is low, President-elect Trump's comments yesterday point to additional headline risk and greater support f
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
09:25am, Tuesday, 17'th Dec 2024
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
06:51pm, Monday, 16'th Dec 2024
In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.
US FDA declines to approve injection form of J&J's lung cancer drug
04:17pm, Monday, 16'th Dec 2024
The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.
J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports
03:46pm, Friday, 13'th Dec 2024
Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its
